Full-Time

Scientist – Genomic Medicine Purification

Posted on 3/20/2025

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

No salary listed

Senior

Waltham, MA, USA

Category
Genomics
Medical, Clinical & Veterinary
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Earned PhD (preferred) in Biotechnology, Biochemistry, Chemical Engineering or related discipline OR Master’s degree with 4+ years of relevant experience OR Bachelor’s degree with 6+ years of relevant experience
  • Technical experience in modern analytical techniques such as spectrophotometry, ELISA, DLS, Octet, QPCR/ddPCR, HPLC, and CE-SDS
  • Significant experience, knowledge and understanding of purification technologies and operations (required) such as: Filtration unit operations at various scales, including depth filtration, tangential flow filtration, etc.; Protein purification chromatography; Virus clearance and inactivation
  • Expertise in technical report writing is necessary
  • Familiarity with advanced purification technologies and process analytical technologies is helpful
Responsibilities
  • Lead and conduct viral/non-viral vector purification process development and process analytics
  • Develop and optimize robust viral/non-viral vector purification process using advanced knowledge of column chromatography, filtration, and other downstream purification technology
  • Develop, conduct, maintain analytical assays such as ELISA, DLS, Octet, QPCR/ddPCR, HPLC, and CE-SDS etc. for in-process sample testing to support process development
  • Provide scientific and technical expertise for in-process sample testing activities, including product quality and process impurity methodologies
  • Perform troubleshooting experiments and communicate findings with appropriate working groups
  • Maintain industry knowledge and keep abreast of new and relevant technologies
  • Perform data analysis, contribute to technical reports, external publications, patent applications and internal/external presentations
  • Lead scale-up activities to implement a manufacturing process based on DSP development knowledge
  • Communicate effectively with internal and external teams, e.g. CDMOs for tech transfer activities
  • Mentor and support junior staff and build a culture of support and collaboration
Desired Qualifications
  • Experience in AAV and/or non-viral purification development
  • Experience in writing CMC components of regulatory dossiers
  • Knowledge of product comparability, target product profile and quality risk assessment activities
  • Viral clearance study design and execution
  • Late-stage purification experience such as design space mapping and process robustness studies
  • Ability to work in Biosafety Level 2, follow safe lab procedures and maintain good laboratory practices (GLPs)
  • Ability to work under minimal supervision and function within a collaborative, team-oriented environment
  • Excellent organization and communication skills
  • Innovative, critical and creative thinker, unafraid of proposing aggressive solutions to complex problems
  • Experience with biophysical characterization
  • Experience in continuous manufacturing and process analytical technology
  • Experience in mentoring junior staff
  • Ability to build and nurture cross-functional relationships
  • Ability to communicate and represent group in diverse, multi-functional meetings

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions like immunology, oncology, and rare diseases. Their products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. Sanofi stands out from competitors by investing significantly in scientific research and forming strategic partnerships to enhance its product pipeline. The goal of Sanofi is to improve health outcomes and the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Dren Bio enhances its biopharmaceutical capabilities.
  • Priority review for tolebrutinib could expedite market entry and boost revenue.
  • Dupixent's positive data in bullous pemphigoid strengthens Sanofi's dermatology portfolio.

What critics are saying

  • Increased competition in MS treatments may impact tolebrutinib's market share.
  • Regulatory delays for Dupixent in bullous pemphigoid could affect revenue.
  • Integration challenges with Dren Bio may impact operational efficiency.

What makes Sanofi unique

  • Sanofi's tolebrutinib targets smoldering neuroinflammation in MS, a unique therapeutic approach.
  • Dupixent shows promise as the first targeted treatment for bullous pemphigoid.
  • Sanofi's Sarclisa is the first anti-CD38 therapy approved for NDMM in the EU.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

PharmiWeb
Mar 25th, 2025
Availability Of The Q1 2025 Aide Mémoire

Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter 2025 results will be published on April 24, 2025.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Berland | + 1 215 432 0234 | [email protected] Obrist | + 33 6 77 21 27 55 | [email protected]éo Le Bourhis | + 33 6 75 06 43 81 | [email protected] Rouault | + 33 6 70 93 71 40 | [email protected] Gilbert | + 1 516 521 2929 | [email protected] RelationsThomas Kudsk Larsen | + 44 75 45 51 36 93| [email protected]é Kaisserian | + 33 6 47 04 12 11 | [email protected] Lauscher | + 1 908 612 7239 | [email protected] Browne | +1 781 249 1766 | [email protected] Pham | + 33 7 85 93 30 17 | [email protected] Elgoutni | + 1 617 710 3587 | [email protected] Châtelet | + 33 6 80 80 89 90 | [email protected] Li | + 33 6 84 00 90 72 | [email protected] statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended

PharmiWeb
Mar 25th, 2025
Tolebrutinib Regulatory Submission Accepted For Priority Review In The Us For Patients With Multiple Sclerosis

If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MSParis, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.The regulatory submissions in the US and the EU are supported by the results from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.Erik Wallström, MD, PhDGlobal Head of Neurology Development“The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct inflammatory process in MS. People living with non-relapsing secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability

BNE
Mar 20th, 2025
Serbian biotech Dren Bio sold to Sanofi for $1.9bn

Pharma-major Sanofi has acquired Serbian-founded biopharmaceutical company Dren Bio for up to $1.9bn, the companies announced in a press release on ...

PharmiWeb
Mar 10th, 2025
Dupixent Late-Breaking Positive Pivotal Data In Bullous Pemphigoid Presented At Aad

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained

Sanofi
Mar 7th, 2025
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Sanofi successfully prices EUR 1.5 billion of bond issue  Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850...

INACTIVE